iWOW Technology Limited announced on Jan, 30 2026 that it has entered into a non-binding term sheet to acquire 100% of a Singapore-based provider of clinically formulated therapeutic meals and rehabilitation solutions for 11.2 million Singapore dollars.

The deal values the target on a fully diluted basis and will be settled through about 7.2 million Singapore dollars in cash and the balance in new iWOW shares to be issued to the target’s founder and chief executive officer.

Completion is subject to customary conditions, including satisfactory due diligence, regulatory and shareholder approvals, funding confirmation, and new service agreements with key employees. The parties have agreed to a three-month exclusivity period to finalise a definitive sale-and-purchase agreement.

iWOW said the proposed acquisition aligns with its plan to broaden its presence in the silver-economy market by combining its technology and AI capabilities with the target’s nutrition expertise. The company expects the deal to enhance recurring revenue, expand its customer base in both B2B and B2C segments, and support future regional expansion.

The transaction is expected to qualify as a disclosable transaction under Chapter 10 of the Singapore Exchange’s Catalist Rules. iWOW added that there is no certainty the definitive agreement will be executed or that the acquisition will proceed as outlined.

Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.